- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: NSC 21548, Deoxythymidine, 2'-Deoxythymidine, 5-Methyldeoxyuridine, DThyd 中文名稱:胸苷
Thymidine是嘧啶核苷,由連接至糖脫氧核糖的嘧啶堿基胸腺嘧啶組成。作為DNA的組成部分,胸腺嘧啶核苷與DNA雙螺旋中的腺嘌呤配對。
Thymidine Chemical Structure
CAS: 50-89-5
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
ONS | Function assay | 10 uM | 24 hrs | Induction of phenotypic perturbation in human ONS cells assessed as decrease in EEA1-associated early endosomes level in at 10 uM after 24 hrs by EEA1 staining based assay relative to control | 26883470 |
ONS | Function assay | 10 uM | 24 hrs | Induction of phenotypic perturbation in human ONS cells assessed as decrease in autophagy markers level in at 10 uM after 24 hrs relative to control | 26883470 |
HEL | Antiviral assay | 3 days | Antiviral activity against Human adenovirus 2 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method, EC50 = 22 μM. | 30286952 | |
Vero | Antiviral assay | Anti-Herpes simplex virus type-1 activity in vero cells using plaque inhibition assay, IC50 = 0.0003 μM. | 10464017 | ||
HepG2.2.15 | Antiviral assay | Antiviral activity against HBV in HepG2.2.15 cells assessed as decrease in extracellular viral DNA level by RT-PCR, EC50 = 0.3 μM. | 17404006 | ||
HL-60 | Function assay | The compound was tested for [3H]TdR incorporation into DNA in HL-60 cells, ID50 = 0.61 μM. | 2840503 | ||
Vero | Function assay | Compound was evaluated for Kinetic constant for cellular thymidine kinase in Vero cells, Km = 0.81 μM. | 3033244 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Thymidine是嘧啶核苷,由連接至糖脫氧核糖的嘧啶堿基胸腺嘧啶組成。作為DNA的組成部分,胸腺嘧啶核苷與DNA雙螺旋中的腺嘌呤配對。 |
---|
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT01199250 | Not yet recruiting | Lynch Syndrome|Recurrent Uterine Corpus Carcinoma|Stage I Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer |
Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
January 2100 | -- |
NCT04598516 | Withdrawn | Acute Kidney Injury (Nontraumatic)|Contrast-induced Nephropathy|Renal Insufficiency |
Maastricht University Medical Center |
November 1 2097 | -- |
NCT05454306 | Suspended | Clavicle Fracture |
University of Minnesota |
January 9 2028 | Not Applicable |
NCT04795856 | Not yet recruiting | Mitral Valve Regurgitation |
University of Alabama at Birmingham |
June 18 2027 | Early Phase 1 |
NCT06359262 | Not yet recruiting | Mental Health Wellness 1 |
Karolinska Institutet |
January 1 2027 | Not Applicable |
分子量 | 242.23 | 分子式 | C10H14N2O5 |
CAS號 | 50-89-5 | SDF | Download Thymidine SDF |
Smiles | CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 48 mg/mL ( (198.15 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : 48 mg/mL (198.15 mM) Ethanol : 9 mg/mL (37.15 mM) |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項